Augmedix, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Net loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Increase in accrued expenses
Depreciation
Share-based compensation
Non-cash lease expense
Non-cash interest expense
Non-cash advertising expense
Non-cash portion of loss on debt extinguishment
Forgiveness of PPP loan
Change in fair value of warrant liability
(Gain) loss on disposal of property and equipment
Provision for bad debt
Deferred rent

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Deposits
Deposits and other assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenues
Deferred revenue
Operating lease liability
Customer deposits
Net cash used in operating activities

Cash flows from investing activities:
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Cash paid in connection with the Merger, net of cash acquired
Payment to unaccredited investors of Augmedix Operating Corporation
Proceeds from stock subscription receivable
Proceeds from issuance of convertible preferred stock
Proceeds from exercise of common stock warrants
Payment of offering costs in relation to common stock issuance
Proceeds from exercise of stock options
Proceeds from issuance of convertible notes payable
Proceeds from loan payable
Proceeds from note payable
Repayment of note payable
Repayment of Eastward Loan
Payment of financing costs
Net cash provided by (used in) financing activities

Net change in cash
Cash, beginning of period
Cash, end of period
Effect of exchange rate changes on cash and restricted cash
Net increase (decrease) in cash and restricted cash
Cash and restricted cash at beginning of year
Cash and restricted cash at end of year
Supplemental disclosure of cash flow information:
Cash paid during the year for interest
Cash paid during the year for taxes
Cash paid for operating lease liabilities
Supplemental schedule of non-cash investing and financing activities:
Conversion of convertible preferred stock to shares of common stock
Amounts due to unaccredited investors of Augmedix Operating Corporation
Financing fees in accrued expenses
Issuance of convertible preferred stock in exchange for convertible notes payable and accrued interest
Beneficial conversion feature related to convertible notes payable
Fair value of common stock issued to service provider
Property, plant, and equipment in accounts payable
Fair value of warrants issued in connection with loan
Purchases of property, plant, and equipment in accounts payable and accrued expenses and other liabilities
Operating lease right-of-use asset exchanged for operating lease liability

Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash and cash equivalents
Restricted cash
Restricted cash, non-current

Comments